Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPM1D | O15297 | 2/20 | 0.34 |
| ▸ | CCR5 | P51681 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | PPARG | P37231 | 1/20 | 0.31 |
| ▸ | PPARA | Q07869 | 1/20 | 0.31 |
| ▸ | REN | P00797 | 1/20 | 0.31 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.30 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.30 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24497048 | 0.92 | POLB (0.35) | POLBPDK2 | |
| SCHEMBL24497049 | 0.90 | POLB (0.36) | POLBPDK2 | |
| SCHEMBL24490466 | 0.89 | PDK2 (0.36) | POLBPDK2 | |
| SCHEMBL25711214 | 0.89 | POLB (0.34) | POLBPDK2 | |
| SCHEMBL22355421 | 0.84 | PDK2 (0.36) | POLBPDK2 | |
| SCHEMBL24490489 | 0.84 | POLB (0.37) | POLBPDK2 | |
| SCHEMBL24490437 | 0.83 | PDK2 (0.36) | POLBPDK2 | |
| SCHEMBL18123001 | 0.82 | PDK2 (0.37) | POLBPDK2 | |
| SCHEMBL22355444 | 0.81 | POLB (0.37) | POLBPDK2 | |
| SCHEMBL18122990 | 0.81 | PDK2 (0.37) | POLBPDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230242692-A1 | COMPOSITION AND CURED PRODUCT | TOKYO OHKA KOGYO CO., LTD. (JP) | 2023-08-03 | — | — | US | disclosed |
| US-20220177641-A1 | CURABLE COMPOSITION, CURED PRODUCT, AND COMPOUND | TOKYO OHKA KOGYO CO., LTD. (JP) | 2022-06-09 | — | — | US | disclosed |
| US-20220177673-A1 | CURABLE COMPOSITION, CURED PRODUCT, AND COMPOUND | TOKYO OHKA KOGYO CO., LTD. (JP) | 2022-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220177641-A1 | CURABLE COMPOSITION, CURED PRODUCT, AND COMPOUND | CROCC, RCSD1, WDR5 | PPM1D 3326/4885CCR5 4368/4885POLB 1946/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.